Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Assets (2016 - 2025)

Ani Pharmaceuticals' Non-Current Assets history spans 16 years, with the latest figure at $687.3 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 9.09% year-over-year to $687.3 million; the TTM value through Dec 2025 reached $2.9 billion, up 27.96%, while the annual FY2025 figure was $687.3 million, 9.09% down from the prior year.
  • Non-Current Assets for Q4 2025 was $687.3 million at Ani Pharmaceuticals, down from $709.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $766.1 million in Q3 2024 and bottomed at $279.1 million in Q3 2021.
  • The 5-year median for Non-Current Assets is $422.4 million (2022), against an average of $487.4 million.
  • The largest annual shift saw Non-Current Assets fell 13.14% in 2021 before it surged 102.68% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $449.8 million in 2021, then fell by 7.56% to $415.8 million in 2022, then decreased by 7.51% to $384.6 million in 2023, then skyrocketed by 96.57% to $756.0 million in 2024, then fell by 9.09% to $687.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Non-Current Assets are $687.3 million (Q4 2025), $709.8 million (Q3 2025), and $740.4 million (Q2 2025).